Pharmafile Logo

Trulicity

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Trulicity in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Trulicity.

15

Global Revenue Ranking

Recent articles on PMLiVE featuring Trulicity

- PMLiVE
Lilly announces agreement with US government to lower patient costs

The agreement will make insulin and obesity treatments more affordable through federal programmes and direct-to-patient channels

- PMLiVE
Eli Lilly’s Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients

Approximately 38.4 million people in the US are affected by diabetes

- PMLiVE
Eli Lilly announces $450m investment in US manufacturing site

In December 2022 increased demand resulted in a short supply of two of its diabetes drugs

- PMLiVE
Havas Health & You appoints Laura Mizrahi as chief creative officer of H4B Chelsea

Mizrahi joins the agency from her role as executive creative director at FCB Health NY

- PMLiVE
Eli Lilly focuses on 2022 launches as revenues climb by 18%

Revenues in the third quarter of 2021 were driven by volume growth in new medicines, but earnings per share were a fraction below analysts’ predictions

- PMLiVE
Lilly cuts 2021 guidance to reflect ‘lower expected revenue’ from COVID-19 antibody sales

FDA recently removed emergency authorisation for bamlanivimab monotherapy

- PMLiVE
Lilly’s tirzepatide shows superiority over Novo’s semaglutide in type 2 diabetes trial

Lilly’s drug beat semaglutide 1mg on multiple measures including weight loss

- PMLiVE
Lilly’s Q3 earnings slump on COVID-19 development costs, pricing pressures

Earnings were particularly impacted by lower demand for top diabetes drug Trulicity

- PMLiVE
Could formulary intelligence be your brand differentiator?

Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch

- PMLiVE
Lilly’s Trulicity scores CV reduction indication in the US

Approved for risk reduction in primary and secondary populations

- PMLiVE
New drugs drive Novo Nordisk despite insulin price pressures

Sales growth of new products up in Q4 but trouble forecasted this year

- PMLiVE
Lilly posts higher-than-expected profit as new drugs lift outlook

Sales boosted by growth of Trulicity and Taltz

Data provided by GlobalData

GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.

Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.

To find out more about how our research and insights can help you, please visit  https://www.globaldata.com/who-we-are/why-globaldata/

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links